An Article in Press is an early-access version of the accepted, peer-reviewed manuscript. It is not a preprint in the informal sense: it has passed editorial assessment and external peer review, and it carries a permanent Digital Object Identifier, or DOI. That DOI is the crucial technical detail. Because the identifier is assigned at the Article in Press stage and retained when the final version is published, any citation made to the early version remains valid indefinitely. Researchers can view, share, and cite the work immediately, and the citation will continue to resolve correctly after the finished Version of Record replaces the preliminary text.

The system exists because producing a final journal article involves more than acceptance. After peer review concludes, the manuscript moves into copyediting, typesetting, and author proofing. During these stages, errors affecting the content may be discovered, and the Article in Press may be subject to further editing. Errors found in the early version are corrected during the author proofing stages of production, and those corrections are reflected in the final Version of Record. In other words, the early version is a snapshot of the accepted science, while the Version of Record is the fully refined, publisher-formatted article.

Transparency is a central feature of the model. An Article in Press is clearly labelled online to show that it is not the final Version of Record. This labelling protects readers by making the status of the document unambiguous: anyone encountering the paper knows they are looking at an accepted manuscript that may still undergo minor changes. All legal disclaimers relating to the journal apply to the early version just as they do to the final one, so the same ethical and legal framework governs both stages of publication.

When the final Version of Record is published, it replaces the Article in Press while retaining the same DOI. This continuity matters for the scholarly record. Citation counts, reference links, and database indexing all attach to the DOI rather than to a particular rendering of the text. Because the identifier never changes, the transition from early version to final version is seamless for readers, libraries, and indexing services. Nothing in the citation chain breaks, and no duplicate records accumulate under different identifiers.

The model is closely tied to open access publishing. Fully open access journals provide this service on every accepted manuscript, meaning that no accepted paper waits in a production queue before becoming publicly visible. For pharmacology and toxicology research, where findings can inform drug safety decisions, clinical practice, and regulatory thinking, the speed advantage is significant. A study on a drug interaction or a toxicological mechanism can be read and cited by other researchers the moment it is accepted, rather than weeks later.

For authors, the Article in Press stage also offers a practical communications opportunity. Researchers who wish to organise a press release for their accepted paper are advised to contact their production editor as early as possible. Early coordination allows institutional press offices and journal production teams to align their timelines, so that media coverage can coincide with the paper becoming publicly available rather than trailing behind it by several weeks.

The distinction between an Article in Press and other forms of early sharing is worth understanding. Preprints, posted on servers before peer review, communicate findings quickly but carry no guarantee of quality control. Articles in Press occupy a different position: peer review is complete, the journal has accepted the work, and a permanent DOI exists, yet final copyediting and proofing remain outstanding. For readers weighing the reliability of a new paper, that status label is a meaningful signal about how far the manuscript has travelled through the publication pipeline.

Springernature, the publisher behind the BMC journal portfolio, maintains public documentation explaining the Article in Press process through its support resources. Authors and readers who want more detail about how early-access versions are handled, corrected, and ultimately replaced can consult these guides directly. The documentation reinforces the core promise of the system: that early visibility never comes at the cost of a stable, permanent scholarly record.

As scientific publishing continues to accelerate, the Article in Press model illustrates how journals balance two competing demands: the community’s desire for immediate access to new findings, and the need for careful, error-free final versions. By publishing accepted manuscripts immediately under a permanent DOI, labelling them clearly as preliminary, and correcting any errors discovered during production before the Version of Record appears, journals such as BMC Pharmacology and Toxicology offer researchers the best of both worlds. The science reaches its audience faster, and the permanent record remains as reliable as ever.

Subject of Research: The Article in Press early-access publishing model for accepted peer-reviewed manuscripts

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Articles in Press, BMC Pharmacology and Toxicology, peer review, DOI, Version of Record, open access, early access publishing, scholarly publishing, manuscript acceptance, Springer Nature, author proofing, citation